231 related articles for article (PubMed ID: 2911781)
21. Somatostatin and a long-acting analogue, octreotide acetate. Relevance to dermatology.
Camisa C
Arch Dermatol; 1989 Mar; 125(3):407-12. PubMed ID: 2564269
[No Abstract] [Full Text] [Related]
22. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
Rubin J; Ajani J; Schirmer W; Venook AP; Bukowski R; Pommier R; Saltz L; Dandona P; Anthony L
J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
[TBL] [Abstract][Full Text] [Related]
23. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel).
Khan MS; El-Khouly F; Davies P; Toumpanakis C; Caplin ME
Aliment Pharmacol Ther; 2011 Jul; 34(2):235-42. PubMed ID: 21585408
[TBL] [Abstract][Full Text] [Related]
24. [Therapy of metastatic carcinoid with the somatostatin analog octreotide and with recombinant interferon alfa 2b].
Linkesch M; Kuzmits R; Geyer G
Wien Klin Wochenschr; 1989 Jun; 101(13):455-7. PubMed ID: 2763566
[TBL] [Abstract][Full Text] [Related]
25. Treatment of the carcinoid syndrome with somatostatin, salmon calcitonin, or octreotide.
Antonelli A; Gambuzza C; Bertoni F; Baschieri L
Clin Ther; 1992; 14(2):178-84. PubMed ID: 1377097
[TBL] [Abstract][Full Text] [Related]
26. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
[TBL] [Abstract][Full Text] [Related]
27. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
[TBL] [Abstract][Full Text] [Related]
28. [Analogs of somatostatin and carcinoid tumors].
Gutiérrez Rodero F; Morales Cano JM; de Blas Laborda C; González Barber A
Med Clin (Barc); 1990 Jun; 95(2):78-9. PubMed ID: 2250512
[No Abstract] [Full Text] [Related]
29. Carcinoid tumours and the role of Sandostatin.
Woods HF
NATNEWS; 1989 Jul; 26(7):13-5. PubMed ID: 2779638
[No Abstract] [Full Text] [Related]
30. [Treatment of carcinoid syndrome with ocreotide (SMS-201-995)].
Rodríguez-García JL; Arechaga S; Fraile G; Serrano M
Rev Clin Esp; 1992 Jul; 191(3):168. PubMed ID: 1380173
[No Abstract] [Full Text] [Related]
31. Successful treatment with a long-acting somatostatin analogue (SMS201-995) in a patient with malignant carcinoid syndrome.
Tsuda M; Tamaki S; Iwasaki E; Murashima S; Deguchi K; Shirakawa S
Jpn J Med; 1988 Aug; 27(3):311-6. PubMed ID: 3193661
[TBL] [Abstract][Full Text] [Related]
32. [Therapy of endocrine gastrointestinal-pancreatic tumors with somatostatin analog octreotide].
Arnold R; Neuhaus C; Trautmann ME
Dtsch Med Wochenschr; 1992 Jul; 117(27):1067-71. PubMed ID: 1352235
[No Abstract] [Full Text] [Related]
33. Rapid reversal of carcinoid crisis with a somatostatin analogue.
Kvols LK; Martin JK; Marsh HM; Moertel CG
N Engl J Med; 1985 Nov; 313(19):1229-30. PubMed ID: 2865675
[No Abstract] [Full Text] [Related]
34. [Enteral hyperoxalosis due to therapy with a somatostatin analog].
Ranft K; Eibl-Eibesfeldt B
Dtsch Med Wochenschr; 1990 Feb; 115(5):179-81. PubMed ID: 2298134
[TBL] [Abstract][Full Text] [Related]
35. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.
Strosberg JR; Benson AB; Huynh L; Duh MS; Goldman J; Sahai V; Rademaker AW; Kulke MH
Oncologist; 2014 Sep; 19(9):930-6. PubMed ID: 25096997
[TBL] [Abstract][Full Text] [Related]
36. Octreotide--a synthetic somatostatin.
Med Lett Drugs Ther; 1989 Jul; 31(796):66-8. PubMed ID: 2567960
[No Abstract] [Full Text] [Related]
37. Case report--carcinoid syndrome: two case reports from reserve unit.
Smith DF
J R Nav Med Serv; 2011; 97(2):66-71. PubMed ID: 22013639
[TBL] [Abstract][Full Text] [Related]
38. Mega-dose intravenous octreotide for the treatment of carcinoid crisis: a systematic review.
Seymour N; Sawh SC
Can J Anaesth; 2013 May; 60(5):492-9. PubMed ID: 23328959
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of unstable angina in malignant carcinoid syndrome using the long-acting somatostatin analogue SMS 201-995 (Sandostatin).
Bluming AZ; Berez RR
Am J Med; 1988 Dec; 85(6):872-4. PubMed ID: 3195610
[No Abstract] [Full Text] [Related]
40. Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues.
Arnold R; Frank M; Kajdan U
Digestion; 1994; 55 Suppl 3():107-13. PubMed ID: 7698532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]